Last reviewed · How we verify
Sulphaloxic Acid (SULFALOXIC ACID)
Sulphaloxic Acid (generic name: SULFALOXIC ACID) is a sulfaloxic acid drug. It is currently in Phase 2 development.
Unfortunately, the mechanism of action of Sulphaloxic Acid is not well understood.
Sulphaloxic Acid is a small molecule drug in the sulfaloxic acid class, but details about its development, approval status, and commercial availability are not available. As a result, there is limited information about its target, approved indications, half-life, bioavailability, and generic manufacturers. Sulphaloxic Acid's mechanism of action and key safety considerations are also unknown. Further research is needed to understand its potential therapeutic applications and risks. Without more information, it is challenging to provide a comprehensive summary of this compound.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SULFALOXIC ACID |
|---|---|
| Drug class | sulfaloxic acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
In simple terms, a drug's mechanism of action refers to how it works at a molecular level to produce its therapeutic effect. For Sulphaloxic Acid, this information is currently unavailable, making it difficult to explain how it might interact with the body's systems to treat a particular condition. More research is needed to uncover its mechanism of action.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulphaloxic Acid CI brief — competitive landscape report
- Sulphaloxic Acid updates RSS · CI watch RSS
Frequently asked questions about Sulphaloxic Acid
What is Sulphaloxic Acid?
How does Sulphaloxic Acid work?
What is the generic name of Sulphaloxic Acid?
What drug class is Sulphaloxic Acid in?
What development phase is Sulphaloxic Acid in?
Related
- Drug class: All sulfaloxic acid drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing